Propel Your Biologics Program

As recombinant protein and monoclonal antibody treatments continue to provide promising pathways for both existing indications and new ones, Resilience has the clinical and commercial experience, expertise and capacity to be your preferred manufacturing partner.

Regardless of which of our Biologics teams and facilities across North America take the lead on your project, our goals are the same: to streamline and accelerate your path to first-in-human studies by more efficiently integrating late discovery activities with early development and to apply our clinical and commercial manufacturing excellence to provide robust and reliable supply for your patients.